MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

5/22/24 8:08:34 AM ET

$LEGN

$MXCT

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $LEGN alert in real time by email

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Get the next $LEGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LEGN
$MXCT

Company	Date	Price Target	Rating	Analyst
Legend Biotech Corporation $LEGN	10/8/2024	$86.00	Buy	Redburn Atlantic
Legend Biotech Corporation $LEGN	6/17/2024	$88.00	Buy	Truist
Legend Biotech Corporation $LEGN	5/24/2024	$86.00 → $73.00	Buy	H.C. Wainwright
Legend Biotech Corporation $LEGN	5/23/2024	$60.00	Buy	Deutsche Bank
Legend Biotech Corporation $LEGN	4/17/2024	$65.00	Sector Perform → Sector Outperform	Scotiabank
Legend Biotech Corporation $LEGN	4/3/2024	$82.00	Overweight	Cantor Fitzgerald
Legend Biotech Corporation $LEGN	3/13/2024	$86.00	Outperform	Raymond James
Legend Biotech Corporation $LEGN	12/19/2023		Sector Perform	Scotiabank

More analyst ratings

$LEGN
$MXCT
Press Releases

Fastest customizable press release news feed in the world

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has remained steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health. "Since the Company's inception, MaxCyte set out to commercialize Flow Electroporation® te
11/13/24 8:05:00 AM ET
$MXCT
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarterFirst and only cell therapy clinically shown to significantly extend overall survival versus standard therapies in multiple myeloma patients as early as second line; presented CARTITUDE-4 three-year follow-up data at the International Myeloma Society Annual MeetingInitiated commercial production at Obelisc facility in Ghent, BelgiumLaunched in Switzerland during the third quarter and recently received label expansion into third-line plus settings for multiple myeloma patients Received China's NMPA appro
11/12/24 7:00:00 AM ET
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program. Investors and other interested parties may join the live webcast through this weblink or by visiting Legend Biotech's
11/7/24 7:30:00 AM ET
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care

$LEGN
$MXCT
Market Insights

Live Market Insights

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had discussed plans to split its digital streaming and studio businesses from its legacy television networks. MicroStrategy Inc.’s (NASDAQ:MSTR) stock gained 16.74% last week amid a rise in Bitcoin’s price. D.R. Horton, Inc. (NYSE:DHI) shares surged 12.91% after the company reported better-than-expected Q3 financial results and revised FY24 guidance. The company also authorized a new $4 billion share repurchase. Few analysts raised the price forecasts on the stock. Coinbase Global Inc.’s
7/21/24 9:57:12 AM ET
$COIN
$DHI
$EPAM
$INFY
Finance: Consumer Services
Finance
Homebuilding
Consumer Discretionary
Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70
Scotiabank analyst George Farmer maintains Legend Biotech (NASDAQ:LEGN) with a Sector Outperform and raises the price target from $65 to $70.
7/18/24 4:42:45 PM ET
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-than-expected quarterly EPS and revenues. Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from Benzinga Pro. Cintas shares gained 5.3% to $758.25 on Thursday. Here are some other big stocks recording gains in today’s session. Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares gained 47.6% to $37.29 after the company and Darde
7/18/24 10:29:04 AM ET
$BKU
$CHUY
$COMM
$CSIQ
Savings Institutions
Finance
Restaurants
Consumer Discretionary

$LEGN
$MXCT
Financials

Live finance-specific insights

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarterFirst and only cell therapy clinically shown to significantly extend overall survival versus standard therapies in multiple myeloma patients as early as second line; presented CARTITUDE-4 three-year follow-up data at the International Myeloma Society Annual MeetingInitiated commercial production at Obelisc facility in Ghent, BelgiumLaunched in Switzerland during the third quarter and recently received label expansion into third-line plus settings for multiple myeloma patients Received China's NMPA appro
11/12/24 7:00:00 AM ET
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase of 2% over the third quarter of 2023.Core business revenue of $8.1 million in the third quarter of 2024, an increase of 23% over the third quarter of 2023.No material Strategic Platform License (S
11/6/24 4:05:00 PM ET
$MXCT
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, November 12, 2024, to review third-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approxi
10/24/24 8:00:00 AM ET
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care

$LEGN
$MXCT
Leadership Updates

Live Leadership Updates

Legend Biotech Appoints Alan Bash as President of CARVYKTI®
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg
11/4/24 7:30:00 AM ET
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care
MaxCyte Appoints Cynthia Collins to its Board of Directors
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe
10/15/24 8:05:00 AM ET
$CERT
$MXCT
$PSTX
Computer Software: Prepackaged Software
Technology
Biotechnology: Commercial Physical & Biological Resarch
Health Care
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company's market impact in Cell and
10/10/24 8:05:00 AM ET
$MXCT
Biotechnology: Commercial Physical & Biological Resarch
Health Care

MaxCyte Signs License Agreement With Legend Biotech, Under Which Legend Obtains Non-Exclusive Worldwide License To Use MaxCyte's Flow Electroporation And ExPERT Platform; MaxCyte Eligible For Fees And Miletones

Chat with this insight

Recent Analyst Ratings for $LEGN$MXCT

$LEGN$MXCT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Erck Stanley C exercised 47,689 shares at a strike of $0.04 and sold $177,403 worth of shares (47,689 units at $3.72) (SEC Form 4)

Director Johnston John Joseph exercised 3,000 shares at a strike of $2.93 and sold $11,166 worth of shares (3,000 units at $3.72) (SEC Form 4)

Director Collins Cynthia was granted 51,679 shares (SEC Form 4)

$LEGN$MXCT Press Releases

Fastest customizable press release news feed in the world

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

$LEGN$MXCT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$LEGN$MXCT SEC Filings

President and CEO Masoud Maher bought $489,066 worth of shares (100,000 units at $4.89) (SEC Form 4)

SEC Form S-8 filed by Legend Biotech Corporation

SEC Form 6-K filed by Legend Biotech Corporation

SEC Form 10-Q filed by MaxCyte Inc.

$LEGN$MXCT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Redburn Atlantic initiated coverage on Legend Biotech with a new price target

Truist initiated coverage on Legend Biotech with a new price target

H.C. Wainwright reiterated coverage on Legend Biotech with a new price target

$LEGN$MXCT Market Insights

Live Market Insights

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?

Scotiabank Maintains Sector Outperform on Legend Biotech, Raises Price Target to $70

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday

$LEGN$MXCT Financials

Live finance-specific insights

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

$LEGN$MXCT Leadership Updates

Live Leadership Updates

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

MaxCyte Appoints Cynthia Collins to its Board of Directors

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

$LEGN$MXCT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

Amendment: SEC Form SC 13G/A filed by Legend Biotech Corporation

Recent Analyst Ratings for
$LEGN
$MXCT

$LEGN
$MXCT
Insider Trading

$LEGN
$MXCT
Press Releases

$LEGN
$MXCT
Insider Purchases

$LEGN
$MXCT
SEC Filings

$LEGN
$MXCT
Analyst Ratings

$LEGN
$MXCT
Market Insights

$LEGN
$MXCT
Financials

$LEGN
$MXCT
Leadership Updates

$LEGN
$MXCT
Large Ownership Changes